A5069967189- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Rheumatoid Arthritis Research and Therapies
- Cytokine Signaling Pathways and Interactions
- Systemic Lupus Erythematosus Research
- Peripheral Neuropathies and Disorders
- Ocular Surface and Contact Lens
- Healthcare and Venom Research
- Gene expression and cancer classification
- Blood groups and transfusion
- Glaucoma and retinal disorders
- Liver Diseases and Immunity
- Biological Research and Disease Studies
- Toxin Mechanisms and Immunotoxins
- Genetics, Bioinformatics, and Biomedical Research
- Acute Lymphoblastic Leukemia research
- Erythrocyte Function and Pathophysiology
Ospedale SS. Annunziata
2019-2021
Azienda Ospedaliera Sant'Andrea
2018
University of Chieti-Pescara
2018
Metabolomics based on mass spectrometry represents an innovative approach to characterize multifactorial diseases, such as multiple sclerosis (MuS). To date, the most important biomarker source for MuS diagnosis is cerebrospinal fluid. However, goal research identify new molecules in more easily accessible biological fluids. A very interesting biofluid represented by tears, considered intermediate fluid between and serum. In this work, we developed a merged strategy analysis of lipids...
Background: Alemtuzumab, approved for multiple sclerosis (MS), can cause secondary autoimmune adverse events including thyroid disorders, immune thrombocytopenia (ITP), and glomerular nephropathies. Non-ITP cytopenias are rarely reported. Objective: To report a case of hemolytic anemia (AIHA) nephropathy in MS patient treated with alemtuzumab. Case report: A 34-year-old man developed albuminuria AIHA after the first only alemtuzumab treatment, positive Coombs’ direct indirect tests IgG...
Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the approach. In manuscript entitled "Alemtuzumab treatment multiple sclerosis real-world clinical practice: report from a single Italian center" by di Ioia M. collaborators, efficacy safety data alemtuzumab were evaluated...